Recent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain.
AffiliationPaterson Institute for Cancer Research, Clinical and Experimental Pharmacology Group, University of Manchester, Wilmslow Road, Withington, Manchester, M20 4BX, UK.
MetadataShow full item record
AbstractApoptosis is a fundamental cellular death process that is essential for normal tissue homeostasis, whose deregulation is associated with several human disease states, including cancer. Increased understanding of cancer biology has led to the hypothesis that although cancer cells are inherently resistant to the engagement of apoptosis due to the deregulation of molecular components of core apoptotic machinery or of survival signalling cascades, they are primed to die as a result of microenvironmental and oncogenic proapoptotic stress. Recently, deeper insight into the molecular regulation of apoptosis and, specifically, into its deregulation in cancer has led to the development of promising therapies to restore apoptosis and enable selective tumour cell kill. It is hoped that these mechanism-based therapies will exhibit less problematic toxicity profiles than those of conventional agents. Moreover, the development of tailored therapies directed at malignancies bearing specific alterations in apoptotic or survival signalling components may be used in combination approaches to overcome the resistance to other forms of treatment.
CitationRecent advances in targeting regulators of apoptosis in cancer cells for therapeutic gain. 2006, 15 (6):669-90 Expert Opin Investig Drugs
JournalExpert Opinion on Investigational Drugs
- Apoptosis: the suicide solution in cancer treatment and chemoprevention.
- Authors: Sykiotis GP, Papavassiliou AG
- Issue date: 2006 Jun
- TRAIL receptor signalling and modulation: Are we on the right TRAIL?
- Authors: Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A
- Issue date: 2009 May
- Is TRAIL the holy grail of cancer therapy?
- Authors: Newsom-Davis T, Prieske S, Walczak H
- Issue date: 2009 Apr
- Targeted therapies in gynecologic cancers.
- Authors: Chon HS, Hu W, Kavanagh JJ
- Issue date: 2006 Jun
- Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
- Authors: Hari Y, Harashima N, Tajima Y, Harada M
- Issue date: 2015 Dec 8